Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Treating severe asthma: targeting the IL-5 pathway

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Parent-specific effects on risk of developing allergic sensitization and asthma in childhood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mast cell tryptase enhances wound healing by promoting migration in human bronchial epithelial cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Airway hyperresponsiveness to inhaled mannitol identifies a cluster of non-eosinophilic asthma patients with high symptom burden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. 3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Stefania Principe
  • Celeste Porsbjerg
  • Sisse Bolm Ditlev
  • Ditte Kjaersgaard Klein
  • Korneliusz Golebski
  • Nanna Dyhre-Petersen
  • Yoni E van Dijk
  • Job J M H van Bragt
  • Lente L H Dankelman
  • Sven-Erik Dahlen
  • Christopher E Brightling
  • Susanne J H Vijverberg
  • Anke H Maitland-van der Zee
Vis graf over relationer

Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)-4, IL-5 and IL-13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL-5R and IL-5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late-onset asthma, chronic rhinosinusitis with nasal polyposis, low oral corticosteroids use and low body mass index represent predictive clinical markers of response. Novel Omics studies are emerging with proteomics data and exhaled breath analyses. These may prove useful as biomarkers of response and non-response biologics. Moreover, future biomarker studies need to be undertaken in paediatric patients affected by severe asthma. The choice of appropriate biologic therapy for severe asthma remains challenging. The importance of finding biomarkers that can predict response continuous an open issue that needs to be further explored. This review describes the clinical effects of targeting the IL-5 pathway in severe asthma in adult and paediatric patients, focusing on predictors of response and non-response.

OriginalsprogEngelsk
TidsskriftClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Vol/bind51
Udgave nummer8
Sider (fra-til)992-1005
Antal sider14
ISSN0954-7894
DOI
StatusUdgivet - aug. 2021

ID: 65066147